Parallel Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Parallel Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,413	Closed	-$65K	–	2267
2017 Q4	$65K	Buy	1,413 +25	+2%	+$1.25K	0.01%	619
2017 Q3	$78K	Hold	1,388	–	–	0.01%	550
2017 Q2	$39K	Sell	1,388 -400	-22%	-$9.87K	0.01%	766
2017 Q1	$45K	Sell	1,788 -100	-5%	-$2.15K	0.01%	681
2016 Q4	$36K	Buy	+1,888	New	+$46.2K	0.01%	678

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Parallel Advisors's JUNO Position: Q1 2018 in Review

Parallel Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,413 shares — an estimated $65K sold.

Parallel Advisors first reported a position in JUNO in Q4 2016 and held it in 5 quarters. The position peaked at $78K in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Parallel Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Parallel Advisors sold 1,413 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $65K.
Parallel Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 5 quarters.
Parallel Advisors's Juno Therapeutics, Inc. position peaked at $78K in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Parallel Advisors's 13F filing for Q1 2018, filed 8 May 2018.